泛自閉症障礙（ASD）：新興療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 受診斷和服務利用率提高的推動，德國 ASD 市場預計將從2025年的3,590萬美元成長到2035年的4,650萬美元。
• 市場擴張主要受以下因素驅動：
• 對行為療法、發展療法和支持療法的需求不斷成長。
• 提高公眾意識和早期診斷的進展
• 由於治療選擇有限，且高度依賴非藥物療法，市場仍相對受限。
• 未來的成長取決於針對核心症狀的標靶治療的開發，以及早期療育和支持服務的持續擴展。

泛自閉症障礙（ASD）的新治療方法及對 TPP 的深入理解

Thelansis 發布的《泛自閉症障礙（ASD）：新興治療方法報告，包括未滿足的需求和目標產品概況（TPP）見解 -2026》對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況（TPP）、試驗設計和關鍵意見領袖（KOL）見解領袖。

泛自閉症障礙（ASD）概述

泛自閉症障礙（ASD）是一種複雜多樣的神經發育障礙，其特徵是行為、興趣或活動模式受限且重複，並伴隨持續的社交溝通和互動障礙。此障礙涵蓋了頻譜的功能能力，從需要終身大量支持的個體到高度獨立的個體不等。

自閉症譜系障礙（ASD）的病因複雜，包括多種因素，包括重要的遺傳因素以及父母高齡、早產等環境風險因素。此外，它還與某些遺傳疾病有關，例如脆弱X染色體症候群。臨床症狀多種多樣，可能包括感覺處理差異（感覺過敏或感覺遲鈍）、語言發展遲緩，以及在某些情況下，幼兒早期發展障礙。

治療方法正朝著個人化照護模式發展，這種模式重視神經多樣性，並強調早期和持續介入。標準方法包括行為療法、語言療法、職業療法和教育支持，目的是提高患者的功能獨立性、溝通能力和生活品質。目前尚無藥物療法能夠改變疾病狀態，現有藥物主要針對相關症狀（例如，易怒、焦慮等）。

主要亮點

• 在美國，預計到2025年，該疾病患者總數將達到 400萬，到2035年將達到 430萬，呈現穩定成長趨勢（年複合成長率為 0.7%）。
• 這種疾病具有極強的異質性，功能障礙程度和支持需求各不相同，需要複雜且個人化的照護途徑。
• 缺乏疾病修正治療，以及依賴長期行為療法和支持性干預措施，凸顯了巨大的未滿足需求。

來自對醫生和關鍵意見領袖（KOL）的調查的見解：

• 透過對關鍵意見領袖（KOL）的訪談，獲得了更多見解，進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興治療方法的患者
• 主要企業
• 主要作用機制
• 發布日期等的預測
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等
• 未滿足的需求和機會
• 目前主要治療方法的有效性
• 未滿足需求的關鍵領域
• 估算主要未滿足需求的市場規模
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵KOL洞察對領先新興治療方法的見解
• 意識
• 預期用途/處理線
• 對主要未滿足需求的滿意度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

主要企業

• MapLight Therapeutics
• Bazelet Nehushtan Ltd.
• Aardvark Therapeutics, Inc.
• AbbVie
• Floreo, Inc.
• Jazz Pharmaceuticals
• Astrogen, Inc.
• Definium Therapeutics US, Inc.
• Neuroventi Inc.
• Vertero Therapeutics
• Shanghai Auzone Biological Technology Co., Ltd.
• Hoffmann-La Roche
• Intra-Cellular Therapies, Inc.
• Bristol-Myers Squibb
• ACADIA Pharmaceuticals Inc.
• Otsuka Pharmaceutical Development &Commercialization, Inc.

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法 - 概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章 未滿足的需求與目標產品分析

• 主要未滿足的需求及其未來透過新興治療方法實現的可能性
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Autism Spectrum Disorder (ASD) Emerging Therapy and TPP Insights

Thelansis's "Autism Spectrum Disorder (ASD) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Autism Spectrum Disorder (ASD) Overview

Autism Spectrum Disorder (ASD) is a complex, heterogeneous neurodevelopmental condition characterized by persistent deficits in social communication and interaction, along with restricted and repetitive patterns of behavior, interests, or activities. The disorder encompasses a broad spectrum of functional abilities, ranging from individuals requiring substantial lifelong support to those with high levels of independence.

The etiology of ASD is multifactorial, with strong genetic contributions alongside environmental risk factors such as advanced parental age and prematurity. It is also associated with certain genetic conditions, including Fragile X Syndrome. Clinical presentation varies widely and may include sensory processing differences (hyper- or hyporeactivity), language delays, and in some cases, developmental regression during early childhood.

Management has evolved toward a neurodiversity-affirming, individualized care model, focusing on early and sustained interventions. Standard approaches include behavioral therapy, speech-language therapy, occupational therapy, and educational support aimed at improving functional independence, communication, and quality of life. There are currently no disease-modifying pharmacological therapies, with available medications primarily targeting associated symptoms (e.g., irritability, anxiety).

Key Highlights

• In the US, total prevalent cases are projected to increase from 4.0M in 2025 to 4.3M by 2035, reflecting steady growth (0.7% CAGR).
• The condition is highly heterogeneous, with varying levels of functional impairment and support needs, contributing to complex and individualized care pathways.
• Absence of disease-modifying therapies and reliance on long-term behavioral and supportive interventions highlight a significant unmet need.

Market Overview

• The Germany ASD market is projected to grow from $35.9M in 2025 to $46.5M by 2035, reflecting moderate growth aligned with increasing diagnosis and service utilization.
• Market expansion is primarily driven by:
• Increased demand for behavioral, developmental, and supportive therapies
• Rising awareness and earlier diagnosis
• The market remains relatively constrained due to limited pharmacological treatment options and a strong reliance on non-drug interventions.
• Future growth will depend on the development of targeted therapies addressing core symptoms, alongside continued expansion of early intervention and support services.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• MapLight Therapeutics
• Bazelet Nehushtan Ltd.
• Aardvark Therapeutics, Inc.
• AbbVie
• Floreo, Inc.
• Jazz Pharmaceuticals
• Astrogen, Inc.
• Definium Therapeutics US, Inc.
• Neuroventi Inc.
• Vertero Therapeutics
• Shanghai Auzone Biological Technology Co., Ltd.
• Hoffmann-La Roche
• Intra-Cellular Therapies, Inc.
• Bristol-Myers Squibb
• ACADIA Pharmaceuticals Inc.
• Otsuka Pharmaceutical Development & Commercialization, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)